Novartis Bet $12 Billion on a Platform. Then the Data Came In.
Novartis shelled out $12 billion for Avidity Biosciences and its muscle-targeting RNA platform. Then a key Phase 3 trial failed, and Wall Street started asking uncomfortable questions about whether the deal was worth it.
Imagine buying a house for $12 billion, then finding out the roof leaks.
That's roughly the situation Novartis finds itself in after acquiring Avidity Biosciences, a San Diego biotech built around a clever technology for delivering RNA drugs into muscle tissue. The price tag: $72 per share, all cash, representing a 46% premium over Avidity's stock price before the deal was announced. The enterprise value: roughly $11 billion. The promise: a pipeline of late-stage neuroscience assets that could power Novartis' growth for years.
The problem? One of those assets just face-planted in a Phase 3 trial.
The Technology That Got Novartis Excited
Avidity's core innovation is something called an antibody-oligonucleotide conjugate, or AOC. Think of it like a biological GPS system. A monoclonal antibody acts as the delivery driver, locking onto a receptor (called TfR1) that's abundant on the surface of muscle cells. Attached to that antibody is an oligonucleotide: a small piece of genetic material that, once inside the cell, can silence harmful genes or fix broken RNA.
Getting RNA-based drugs into muscle has historically been like trying to deliver a pizza to someone inside a locked building. The pizza exists; you just can't get it through the door. Avidity's platform was supposed to be the key.
And for a while, it looked like it was working.
Three Programs, Three Very Different Stories
Avidity brought three main clinical programs to the table, each targeting a different neuromuscular disease.
Del-zota, the star of the portfolio, targets Duchenne muscular dystrophy (DMD) in patients amenable to exon 44 skipping. Its Phase 1/2 trial delivered genuinely impressive results: statistically significant exon skipping, dystrophin levels averaging about 25% of normal (a meaningful threshold), and creatine kinase reductions of over 80%, bringing levels close to healthy range. The safety profile looked clean. Avidity even launched a U.S. managed access program, which is biotech-speak for "we're confident enough to start giving this to patients outside of trials."
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Del-brax, targeting facioscapulohumeral muscular dystrophy (FSHD), showed positive Phase 1/2 data as well, though it's still early-stage without a pivotal trial readout yet.
Then there's del-desiran.
The $1.6 Billion Roof Leak
Del-desiran was designed to treat myotonic dystrophy type 1 (DM1), the most common form of adult-onset muscular dystrophy. Its Phase 3 trial, called HARBOR, was supposed to be a crown jewel of the Avidity acquisition. Instead, the study failed to meet its primary endpoint: patients on the drug didn't show a statistically significant improvement in hand-opening function compared to placebo.
For a $12 billion deal, that stings.
JPMorgan estimated del-desiran's risk-adjusted peak sales at roughly $3 billion, which sounds enormous until you realize it's less than 3% of Novartis' expected annual revenue. By the numbers, it's a flesh wound. By the optics, it's something worse.
Wall Street's Trust Problem
The market reaction went beyond what the direct financial hit would justify, and that tells you something important. Investors aren't just worried about one failed trial. They're worried about whether Novartis knows how to spend $12 billion wisely.
Guggenheim analysts had flagged del-desiran's success as "crucial" for validating the entire Avidity transaction. And Artisan Partners' M. David Samra went further, publicly criticizing the company's acquisitions and arguing management should face consequences if a deal this size goes to zero.
Not everyone is piling on, though. Analysts at Bellevue Asset Management pointed out that the HARBOR trial was designed before Novartis even bought Avidity, meaning you can't exactly blame the new owner for the blueprints. Union Investment echoed a similar sentiment: drug development is inherently risky, and a single Phase 3 miss doesn't invalidate an entire platform.
The question is whether that nuance matters when shareholder trust is already fragile.
The SpinCo Wrinkle
Buried in the deal structure is a detail worth noting. Before closing, Avidity was set to carve out its early-stage precision cardiology programs (targeting conditions like PLN and PRKAG2 syndrome) into a separate company called SpinCo, later named Bryce Therapeutics.
Avidity shareholders would receive one SpinCo share for every ten Avidity shares they held, and Bryce would be capitalized with $270 million in cash. The new company was expected to be led by Kathleen Gallagher as CEO, with Avidity's Sarah Boyce chairing the board.
It's a clever structure: Novartis gets the neuromuscular pipeline it wants, and shareholders keep a piece of the cardiology upside. Whether Bryce Therapeutics becomes something meaningful on its own is a story for another day.
Why Novartis Pulled the Trigger Anyway
Novartis has been telegraphing this move for years. Neuroscience is one of its four core therapeutic pillars, alongside oncology, immunology, and cardiovascular-renal-metabolic. The segment generated $6 billion in sales in 2025, up 26% year-over-year, driven mostly by Kesimpta (its blockbuster MS drug). Leadership has described the company as "pretty aggressive and active" in neuroscience business development.
The Avidity deal fits a clear pattern: Novartis wants late-stage, de-risked neuromuscular assets built on RNA or gene therapy platforms. Del-zota's DMD data is genuinely exciting. The AOC platform, if it works broadly, could be a franchise unto itself. Even del-brax has early promise.
But the HARBOR failure complicates the narrative. It raises a fundamental question about whether AOCs can consistently deliver results across different diseases, or whether del-zota's success is the exception rather than the rule.
The Bottom Line
Novartis didn't buy Avidity for one drug. It bought a platform and a pipeline, betting that the ability to deliver RNA therapeutics directly into muscle tissue would be transformative across multiple diseases. That thesis isn't dead; del-zota's data alone makes a strong case.
The real risk isn't scientific. It's strategic. At $12 billion, Novartis doesn't have the luxury of patience. Every future readout from the AOC platform will be scrutinized not just as clinical data, but as a referendum on whether this deal was worth it. And if del-brax stumbles too, the trust concerns investors have raised won't just be a talking point. It'll be a full-blown credibility crisis.
For now, Novartis owns the key to the building. They just need to prove there's more than one pizza worth delivering inside.
4 min read
Merck Just Paid $400M for a Drug That Doesn't Exist Yet
Merck just dropped $400 million on a Chinese biotech's preclinical cancer drug targeting a protein scientists called "undruggable" for 40 years. The KRAS G12D race is on, and Merck's gamble says everything about where Big Pharma is shopping for its next blockbuster.
